Post by norfoster on Oct 26, 2017 17:56:17 GMT
alphastreet.com/b0662389 Chaos continues for Celgene. A cut in outlook, especially it’s long-term targets, is not an encouraging one. Also, a decrease in biotech company’s R&D expenses is not a good sign.